Table 1.

Baseline characteristics and outcomes

	Sarcopenia N=72	No Sarcopenia N=70	P value
Median Age at Transplant (range)	63.3 (38.2–78.6)	59.7 (43.8–78.7)	0.7
Male (%)	46 (63.9%)	46 (65.7%)	0.8
Race (White) (%)	63 (87.5%)	59 (84.3%)	0.6
Median BMI at Transplant (range)	29.0 (21.5–46.1)	28.8 (17.8–40.8)	0.1
Time from Diagnosis to Transplant	5.4 (0.7–30.2)	5.4 (3.3–27.6)	0.6
Stage (ISS)			0.5
ISS-I	25 (36.8%)	22 (33.3%)
ISS-II	27 (39.7%)	25 (37.9%)
ISS-III	16 (23.5%)	19 (28.8%)
Bone Lesions	63 (87.5%)	56 (80.0%)	0.2
Median HCT-CI	1.0 (0.0–8.0)	1.0 (0.0–7.0)	0.7
KPS	48 (66.7%)	44 (62.9%)	0.6
≥90
Lines of Induction			0.2
1	59 (81.9%)	63 (90.0%)
2	13 (18.1%)	7 (10.0%)
Pre-transplant disease status			0.3
≥VGPR	44 (61.1%)	37 (52.9%)
≤PR	28(38.9%)	33 (47.1%)
Melphalan dose			0.6
140 mg/m2	9 (12.5%)	11 (15.7%)
200 mg/m2	63 (87.5%)	59 (84.3%)
Outpatient Transplant	21 (29.2%)	18 (25.7%)	0.6
Day 100 complications
Any Complication	24 (33.3.%)	15 (21.4%)	0.3
Any Adverse Event*	14 (19.4%)	8 (11.4%)	0.2
ICU Transfer	3 (3.5%)	2 (2.9%)	0.7
Cardiovascular Event	9 (12.5%)	2 (2.9%)	0.03
Renal Failure	2 (2.9%)	0 (0.0%)	0.2
Respiratory Failure	0 (0.0%)	0 (0.0%)	NA
Sepsis	6 (8.3%)	7 (10.0%)	0.7
Unplanned hospitalization	17 (23.6%)	11 (15.7%)	0.2
Total days spent in hospital	12.0 (0.0–40.0)	12.0 (0.0–43.0)	0.8
Discharge to rehab facility	3 (4.2)	4 (5.7)	0.7
Median f/u as survivors (months)	27.2 (12.4–71.3)	33.0 (12.8–74.3)	0.09

^*Any adverse event describes any patient experiencing cardiovascular event, renal failure, respiratory failure, sepsis, or ICU transfer. If one patient experienced more than one adverse event, it is reported as one adverse event by this definition.

Similarly, any complication (CV, renal, respiratory, sepsis, ICU transfer, unplanned hospitalization) is reported as complication per patient. If one patient experienced more than one complication, it is reported as one in this category.